These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

277 related articles for article (PubMed ID: 21925447)

  • 1. [Rituximab in rheumatoid arthritis: a systematic review of efficacy and safety].
    Hernández-Cruz B; García-Arias M; Ariza Ariza R; Martín Mola E
    Reumatol Clin; 2011; 7(5):314-22. PubMed ID: 21925447
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of rituximab with and without methotrexate in the treatment of rheumatoid arthritis patients: results from the GISEA register.
    Sebastiani M; Anelli MG; Atzeni F; Bazzani C; Farina I; Fedele AL; Favalli EG; Fineschi I; Cino N; Dal Forno I; Gasparini S; Cassarà E; Giardina R; Bruschi E; Addimanda O; Cassone G; Lopriore S; Sarzi-Puttini P; Filippini M; Pignatti F; Gremese E; Biggioggero M; Manganelli S; Amato G; Caimmi C; Salaffi F; Iannone F; Ferri C; Sandri G; Lapadula G; Gorla R; Govoni M; Ferraccioli G; Marchesoni A; Galeazzi M; Foti R; Carletto A; Cantini F; Triolo G; Epis OM; Salvarani C;
    Joint Bone Spine; 2014 Dec; 81(6):508-12. PubMed ID: 25082646
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative effectiveness of rituximab in combination with either methotrexate or leflunomide in the treatment of rheumatoid arthritis.
    Narváez J; Díaz-Torné C; Ruiz JM; Hernández MV; Torrente-Segarra V; Ros S; Rodriguez de la Serna A; Díaz-López C; Sanmartí R; Nolla JM
    Semin Arthritis Rheum; 2011 Dec; 41(3):401-5. PubMed ID: 21862107
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of switching from rituximab to biosimilar CT-P10 in rheumatoid arthritis: 72-week data from a randomized Phase 3 trial.
    Shim SC; Božić-Majstorović L; Berrocal Kasay A; El-Khouri EC; Irazoque-Palazuelos F; Cons Molina FF; Medina-Rodriguez FG; Miranda P; Shesternya P; Chavez-Corrales J; Wiland P; Jeka S; Garmish O; Hrycaj P; Fomina N; Park W; Suh CH; Lee SJ; Lee SY; Bae YJ; Yoo DH
    Rheumatology (Oxford); 2019 Dec; 58(12):2193-2202. PubMed ID: 31184752
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy, Safety and Pharmacokinetics of Up to Two Courses of the Rituximab Biosimilar CT-P10 Versus Innovator Rituximab in Patients with Rheumatoid Arthritis: Results up to Week 72 of a Phase I Randomized Controlled Trial.
    Yoo DH; Suh CH; Shim SC; Jeka S; Molina FFC; Hrycaj P; Wiland P; Lee EY; Medina-Rodriguez FG; Shesternya P; Radominski S; Stanislav M; Kovalenko V; Sheen DH; Myasoutova L; Lim MJ; Choe JY; Lee SJ; Lee SY; Kim SH; Park W
    BioDrugs; 2017 Aug; 31(4):357-367. PubMed ID: 28612179
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and effectiveness of rituximab in patients with rheumatoid arthritis following an inadequate response to 1 prior tumor necrosis factor inhibitor: the RESET Trial.
    Haraoui B; Bokarewa M; Kallmeyer I; Bykerk VP;
    J Rheumatol; 2011 Dec; 38(12):2548-56. PubMed ID: 21965646
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The efficacy and safety of rituximab for the treatment of active rheumatoid arthritis: a systematic review and meta-analysis of randomized controlled trials.
    Lee YH; Bae SC; Song GG
    Rheumatol Int; 2011 Nov; 31(11):1493-9. PubMed ID: 20473756
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rituximab or a second anti-tumor necrosis factor therapy for rheumatoid arthritis patients who have failed their first anti-tumor necrosis factor therapy? Comparative analysis from the British Society for Rheumatology Biologics Register.
    Soliman MM; Hyrich KL; Lunt M; Watson KD; Symmons DP; Ashcroft DM;
    Arthritis Care Res (Hoboken); 2012 Aug; 64(8):1108-15. PubMed ID: 22422731
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Study on the possible role of the -174G>C IL-6 promoter polymorphism in predicting response to rituximab in rheumatoid arthritis.
    Fabris M; Quartuccio L; Lombardi S; Benucci M; Manfredi M; Saracco M; Atzeni F; Morassi P; Cimmino MA; Pontarini E; Fabro C; Pellerito R; Sarzi-Puttini P; Cutolo M; Carletto A; Bambara LM; Fischetti F; Curcio F; Tonutti E; De Vita S
    Reumatismo; 2010; 62(4):253-8. PubMed ID: 21253618
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Longterm followup of rituximab therapy in patients with rheumatoid arthritis: results from the Belgian MabThera in Rheumatoid Arthritis registry.
    De Keyser F; Hoffman I; Durez P; Kaiser MJ; Westhovens R;
    J Rheumatol; 2014 Sep; 41(9):1761-5. PubMed ID: 25128506
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predictors of response to rituximab in patients with active rheumatoid arthritis and inadequate response to anti-TNF agents or traditional DMARDs.
    Narvaez J; Díaz-Torné C; Ruiz JM; Hernandez MV; Torrente-Segarra V; Ros S; Rodriguez de la Serna A; Díaz-López C; Sanmartí R; Nolla JM
    Clin Exp Rheumatol; 2011; 29(6):991-7. PubMed ID: 22133052
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rituximab infusion-related adverse event rates are lower in patients with systemic lupus erythematosus than in those with rheumatoid arthritis.
    Conti F; Ceccarelli F; Perricone C; Alessandri C; Conti V; Massaro L; Truglia S; Spinelli FR; Spadaro A; Valesini G
    Rheumatology (Oxford); 2011 Jun; 50(6):1148-52. PubMed ID: 21278072
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effectiveness of rituximab in patients with rheumatoid arthritis: observational study from the British Society for Rheumatology Biologics Register.
    Soliman MM; Hyrich KL; Lunt M; Watson KD; Symmons DP; Ashcroft DM;
    J Rheumatol; 2012 Feb; 39(2):240-6. PubMed ID: 22174201
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of the safety of rituximab in combination with a tumor necrosis factor inhibitor and methotrexate in patients with active rheumatoid arthritis: results from a randomized controlled trial.
    Greenwald MW; Shergy WJ; Kaine JL; Sweetser MT; Gilder K; Linnik MD
    Arthritis Rheum; 2011 Mar; 63(3):622-32. PubMed ID: 21360491
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Updated systematic review and meta-analysis of randomized controlled trials comparing low- versus high-dose rituximab for rheumatoid arthritis.
    Bredemeier M; Campos GG; de Oliveira FK
    Clin Rheumatol; 2015 Oct; 34(10):1801-5. PubMed ID: 26070536
    [TBL] [Abstract][Full Text] [Related]  

  • 16. VARIAR Study: Assessment of short-term efficacy and safety of rituximab compared to an tumor necrosis factor alpha antagonists as second-line drug therapy in patients with rheumatoid arthritis refractory to a first tumor necrosis factor alpha antagonist.
    Torrente-Segarra V; Acosta Pereira A; Morla R; Ruiz JM; Clavaguera T; Figuls R; Corominas H; Geli C; Roselló R; de Agustín JJ; Alegre C; Pérez C; García A; Rodríguez de la Serna A
    Reumatol Clin; 2016; 12(6):319-322. PubMed ID: 26831256
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative effectiveness of switching to alternative tumour necrosis factor (TNF) antagonists versus switching to rituximab in patients with rheumatoid arthritis who failed previous TNF antagonists: the MIRAR Study.
    Gomez-Reino JJ; Maneiro JR; Ruiz J; Roselló R; Sanmarti R; Romero AB;
    Ann Rheum Dis; 2012 Nov; 71(11):1861-4. PubMed ID: 22736086
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Infection risks of rituximab versus non-rituximab treatment for rheumatoid arthritis: A systematic review and meta-analysis.
    Shi Y; Wu Y; Ren Y; Jiang Y; Chen Y
    Int J Rheum Dis; 2019 Aug; 22(8):1361-1370. PubMed ID: 31099191
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of biosimilar CT-P10 and innovator rituximab in patients with rheumatoid arthritis: a randomized controlled Phase 3 trial.
    Park W; Božić-Majstorović L; Milakovic D; Berrocal Kasay A; El-Khouri EC; Irazoque-Palazuelos F; Molina FFC; Shesternya P; Miranda P; Medina-Rodriguez FG; Wiland P; Jeka S; Chavez-Corrales J; Garmish O; Linde T; Rekalov D; Hrycaj P; Krause A; Fomina N; Piura O; Abello-Banfi M; Suh CH; Shim SC; Lee SJ; Lee SY; Kim SH; Yoo DH
    MAbs; 2018; 10(6):934-943. PubMed ID: 30010481
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Low- versus high-dose rituximab for rheumatoid arthritis: a systematic review and meta-analysis.
    Bredemeier M; de Oliveira FK; Rocha CM
    Arthritis Care Res (Hoboken); 2014 Feb; 66(2):228-35. PubMed ID: 23983134
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.